Theravance Dumps JAK Inhibitor Program, Focuses On Neurogenic Orthostatic Hypotension

 
• By Alaric DeArment
  
Theravance announced its fourth quarter and full year 2022 earnings • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business